{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-036122","form_type":"8-K","ticker":"CRDF","cik":"0001213037","company_name":"Cardiff Oncology, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.369201+00:00","generated_at":"2026-05-31T10:42:15.484106+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cardiff Oncology Q2 cash $60.3M; CRDF-004 readout expected 2H 2024","bullets":["Cash and equivalents $60.3M as of June 30, 2024; runway to Q3 2025.","Net cash used in ops $9.2M in Q2 2024 vs $7.1M in Q2 2023.","Total operating expenses $12.7M for Q2 2024, up $0.4M YoY.","CRDF-004 trial for first-line RAS-mutated mCRC data readout expected in 2H 2024.","Preclinical data published on onvansertib + olaparib in olaparib-resistant ovarian cancer."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-036122","json":"https://secwatch.observer/filing/0001628280-24-036122.json","markdown":"https://secwatch.observer/filing/0001628280-24-036122.md","text":"https://secwatch.observer/filing/0001628280-24-036122.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213037/000162828024036122/0001628280-24-036122-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213037/000162828024036122/crdf-20240808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:42:15.484106+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}